3 Results for "

depression diagnosis

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "depression diagnosis" in MCE Product Catalog:

Cat. No.: HY-176036
CAS No.: 3070323-06-4
MS1262 is a blood-brain barrier-permeable, selective inhibitor of histone methyltransferases G9a (EHMT2) and GLP (EHMT1), with an IC50 of 19 nM and a Kd of 74 nM against G9a, and an IC50 of 6 nM and a Kd of 19 nM against GLP. MS1262 reduces the dimethylation level of histone H3 lysine 9 and decreases the size of plaques. MS1262 restores hippocampal long-term potentiation (LTP) and miniature excitatory postsynaptic current (sEPSC) frequency, ameliorates spatial memory deficits, and reverses anxiety-like and depression-like behaviors in AD model mice. MS1262 reverses the expression/phosphorylation levels of early AD biomarkers, providing support for stage-specific diagnosis of AD. MS1262 reduces the risk of thrombus rupture. MS1262 can be used in research related to Alzheimer's disease, colorectal cancer, and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-D2970
Golgi-P is a near-infrared Golgi-targeted fluorescent probe specifically used for the detection of Golgi polarity in living cells and living tissues. Golgi-P exhibits a significant polarity-dependent spectral behavior, with its emission wavelength shifting redward with polarity (Ex/Em: 700 nm/780-825 nm). Golgi-P achieves near-infrared fluorescence imaging directly in the brain tissue of depressed mice. Golgi-P combines polarity sensing with Golgi-targeting functionality, providing a new tool for the molecular diagnosis of depression .
loading...
    loading...
Cat. No.: HY-176036A
MS1262 TFA is a blood-brain barrier-permeable, selective inhibitor of histone methyltransferases G9a (EHMT2) and GLP (EHMT1), with an IC50 of 19 nM and a Kd of 74 nM against G9a, and an IC50 of 6 nM and a Kd of 19 nM against GLP. MS1262 TFA reduces the dimethylation level of histone H3 lysine 9 and decreases the size of plaques. MS1262 TFA restores hippocampal long-term potentiation (LTP) and miniature excitatory postsynaptic current (sEPSC) frequency, ameliorates spatial memory deficits, and reverses anxiety-like and depression-like behaviors in AD model mice. MS1262 TFA reverses the expression/phosphorylation levels of early AD biomarkers, providing support for stage-specific diagnosis of AD. MS1262 TFA reduces the risk of thrombus rupture. MS1262 TFA can be used in research related to Alzheimer's disease, colorectal cancer, and triple-negative breast cancer .
loading...
    loading...